After securing $70 million in series B funding, Chinese biotech Medilink Therapeutics Co. Ltd. is gearing up to enter the clinic with its next-generation antibody-drug conjugates (ADCs).
Ninnion LLC, a startup developing psychedelic medicines focused on brain injury, chronic pain, inflammation and addiction disorders, has formed a new scientific board (SAB) that Chief Development Officer Bill Massey said will ”be a tremendous asset in navigating the uncharted waters of psychedelic drug development."
After securing $70 million in series B funding, Chinese biotech Medilink Therapeutics Co. Ltd. is gearing up to enter the clinic with its next-generation antibody-drug conjugates (ADCs).
Moonlake Therapeutics AG is making headway on its mission to establish a broad dermatology and rheumatology franchise around its sole product, sonelokimab, announcing it is poised to start a phase II study in hidradenitis suppurativa.
Biotechs that tackle the effects of aging are beginning to make headlines: in January Altos Labs Inc. launched with a reported investment from Jeff Bezos. With Bezos getting involved with San Francisco-based Altos, the immediate reaction was that anti-aging biotechs would be there for the benefit of billionaires searching for eternal life.
Not so, according to London U.K.-based Genflow Biosciences plc, which hopes to show that fighting aging is really about improving health as people age.
By combining an activator of the pro-apoptotic protein Bax with an inhibitor of the anti-apoptotic protein BCL-XL, researchers at Albert Einstein College of Medicine have been able to overcome resistance to apoptosis in both a wide range of cell lines and animal studies. The team reported its findings in the March 7, 2022, issue of Nature Communications.
A new study from researchers at Aevisbio Inc. and the National Institutes of Health on the effect of 3,6’-dithiopomalidomide on neuroinflammation adds new detail to what might one day become a significant new therapeutic strategy to treat Alzheimer's disease and other neurological disorders.
Pathalys Pharma Inc., a privately held startup focused on developing new medicines chronic kidney disease, has emerged with an exclusive license from Tokyo-based EA Pharma Co. Ltd. to develop the small molecule calcimimetic upacicalcet for markets outside of Japan and Asia.
After two years of developing its platform, Vesalius Therapeutics Inc. now has $75 million in its pocket from Flagship Pioneering to understand and treat the diseases that account for 90% of the world’s illnesses. To resolve this massive amount of biological and industry complexity, Doug Cole, Vesalius’ chairman and co-founder and Flagship’s managing partner, noted the distinction between illness and disease. “Illness is what bothers you, it’s the experience of being sick and what the doctor might find when you’re examined,” Cole told BioWorld. “Disease is the mechanistic problem with the biology underlying the illness.”
A new study from researchers at Aevisbio Inc. and the National Institutes of Health on the effect of 3,6’-dithiopomalidomide on neuroinflammation adds new detail to what might one day become a significant new therapeutic strategy to treat Alzheimer's disease and other neurological disorders.
RSS
